117 related articles for article (PubMed ID: 582772)
21. Evaluation of encephalotropic and psychotropic properties of gabapentin in man by pharmaco-EEG and psychometry.
Saletu B; Grünberger J; Linzmayer L
Int J Clin Pharmacol Ther Toxicol; 1986 Jul; 24(7):362-73. PubMed ID: 3525428
[TBL] [Abstract][Full Text] [Related]
22. Pharmaco-EEG profile of maroxepine: third example to discuss the predictive value of pharmaco-electroencephalography in early human pharmacological evaluations of psychoactive drugs.
Herrmann WM; Schärer E; Wendt G; Delini-Stula A
Pharmacopsychiatry; 1991 Nov; 24(6):214-24. PubMed ID: 1812498
[TBL] [Abstract][Full Text] [Related]
23. Predictive value of pharmaco-electroencephalography in early human-pharmacological evaluations of psychoactive drugs. First example: savoxepine.
Herrmann WM; Schärer E; Delini-Stula A
Pharmacopsychiatry; 1991 Nov; 24(6):196-205. PubMed ID: 1687485
[TBL] [Abstract][Full Text] [Related]
24. Pharmaco-EEG and psychometric studies with a novel selective benzodiazepine agonist/antagonist Ro 23-0364.
Saletu B; Grünberger J; Cepko H
Int J Clin Pharmacol Ther Toxicol; 1987 Aug; 25(8):421-37. PubMed ID: 2888736
[TBL] [Abstract][Full Text] [Related]
25. Effects of brotizolam on the sleep-waking cycle of the cat.
Kuhn FJ
Arzneimittelforschung; 1986 Mar; 36(3A):522-7. PubMed ID: 3718574
[TBL] [Abstract][Full Text] [Related]
26. Effects of the novel neuroprotective agent, riluzole, on human brain function and behavior: I. Double-blind, placebo-controlled EEG mapping and psychometric studies under normoxia.
Saletu B; Grünberger J; Anderer P; Linzmayer L
Methods Find Exp Clin Pharmacol; 1996; 18(1):55-66. PubMed ID: 8721257
[TBL] [Abstract][Full Text] [Related]
27. Pharmacoelectroencephalographic study of brotizolam, a novel hypnotic.
Fink M; Irwin P
Clin Pharmacol Ther; 1981 Sep; 30(3):336-42. PubMed ID: 7273596
[TBL] [Abstract][Full Text] [Related]
28. Quantitative pharmaco-EEG and performance after administration of brotizolam to healthy volunteers.
Saletu B; Grünberger J; Linzmayer L
Br J Clin Pharmacol; 1983; 16 Suppl 2(Suppl 2):333S-345S. PubMed ID: 6661379
[TBL] [Abstract][Full Text] [Related]
29. A double-blind, placebo- and flurazepam-controlled investigation of the residual psychomotor and cognitive effects of modified release zolpidem in young healthy volunteers.
Blin O; Micallef J; Audebert C; Legangneux E
J Clin Psychopharmacol; 2006 Jun; 26(3):284-9. PubMed ID: 16702893
[TBL] [Abstract][Full Text] [Related]
30. [A quantitative pharmaco-EEG study on psychotropic properties of cerebral metabolic enhancers: comparison between young and elderly healthy volunteers].
Nobuhara K
Seishin Shinkeigaku Zasshi; 1993; 95(5):392-416. PubMed ID: 8356168
[TBL] [Abstract][Full Text] [Related]
31. Pharmaco-EEG profiles of typical and atypical antidepressants.
Saletu B
Adv Biochem Psychopharmacol; 1982; 32():257-68. PubMed ID: 7090895
[TBL] [Abstract][Full Text] [Related]
32. Objective measurements of daytime sleepiness and performance comparing quazepam with flurazepam in two adult populations using the Multiple Sleep Latency Test.
Dement WC
J Clin Psychiatry; 1991 Sep; 52 Suppl():31-7. PubMed ID: 1680123
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
34. BMS-181168 for protection of the human brain against hypoxia: double-blind, placebo-controlled EEG mapping studies.
Saletu B; Schulz H; Herrmann WM; Anderer P; Shrotriya RC; Vanbrabant E
Pharmacopsychiatry; 1994 Sep; 27(5):189-97. PubMed ID: 7838889
[TBL] [Abstract][Full Text] [Related]
35. Clovoxamine and fluvoxamine-2 biogenic amine re-uptake inhibiting antidepressants: quantitative EEG, psychometric and pharmacokinetic studies in man.
Saletu B; Grünberger J; Rajna P; Karobath M
J Neural Transm; 1980; 49(1-2):63-86. PubMed ID: 6777458
[TBL] [Abstract][Full Text] [Related]
36. [Relation between blood levels and average quantitative EEG and psychometrically assessed pharmacodynamic changes following zotepine].
Saletu B; Grünberger J; Anderer P; Chwatal K
Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():45-55. PubMed ID: 1683340
[TBL] [Abstract][Full Text] [Related]
37. Next-day residual effects of gaboxadol and flurazepam administered at bedtime: a randomized double-blind study in healthy elderly subjects.
Boyle J; Wolford D; Gargano C; McCrea J; Cummings C; Cerchio K; Lines C
Hum Psychopharmacol; 2009 Jan; 24(1):61-71. PubMed ID: 18985628
[TBL] [Abstract][Full Text] [Related]
38. The morning after: residual EEG effects of triazolam and flurazepam, alone and in combination with alcohol.
Mendelson WB; Goodwin DW; Hill SY; Reichman JD
Curr Ther Res Clin Exp; 1976 Feb; 19(2):155-63. PubMed ID: 2451
[No Abstract] [Full Text] [Related]
39. Double-blind, placebo-controlled, multiple-ascending-dose study on the pharmacodynamics of ABIO-08/01, a new CNS drug with potential anxiolytic activity. 1. EEG mapping, psychometric and tolerability findings.
Saletu-Zyhlarz GM; Anderer P; Wolzt M; Semlitsch HV; Assandri A; Nessi P; Nannipieri F; Rosini S; Saletu B
Neuropsychobiology; 2009; 59(2):100-9. PubMed ID: 19365150
[TBL] [Abstract][Full Text] [Related]
40. [Electroencephalographic assessment of dosage and sleep-profile in a hypnotic Triazolothienodiazepine (author's transl)].
Kubicki S
EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb; 1979 Jun; 10(2):95-100. PubMed ID: 225156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
